^
    Back
    Association details:
    Biomarker:VTCN1 overexpression
    Cancer:Solid Tumor
    Drug:GEN1047 (CD3 agonist, B7-H4 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    SITC 2022
    Title:

    Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3xB7H4 in solid cancer models

    Published date:
    11/08/2022
    Excerpt:
    DuoBody-CD3xB7H4 demonstrated antitumor activity in ovarian and breast cancer PDX models with high B7H4 expression. Antitumor activity of DuoBody-CD3xB7H4 in an ovarian cancer PDX model was confirmed in a dose-response study...High prevalence of B7H4 expression was observed in primary NSCLC-SCC, ovarian, endometrial, and breast cancer tissue. In vitro, DuoBody-CD3xB7H4 showed antitumor activity across a range of B7H4 expression levels.
    DOI:
    10.1136/jitc-2022-SITC2022.1351